Sensei up after receiving and declining Newtyn's buyout proposal
** Sensei Biotherapeutics's shares SNSE.O rise 21.7% to
$0.84 before the bell
** Co confirmed it had received an unsolicited proposal from
Newtyn Management to acquire all of co's shares for $1/share in
cash
** Offer at nearly 45% premuim to SNSE's last close
** SNSE's board rejected Newtyn's proposal citing the
proposal undervalued co's future prospect
** Up to Friday's close, stock had fallen ~54% YTD
(Reporting by Khushi Mandowara in Bengaluru)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments